Background Bone loss in patients (pts) with early axial spondyloarthritis (axSpA) is insufficiently studied and may be associated with disease activity.
Objectives To assess the bone mineral density (BMD) in pts with early axSpA base on data from 2 years follow up of CORSAR cohort.
Methods The research included 65 pts with axSpA (criteria ASAS 2009) with disease duration <5 years and age at onset <45 years. Pts at least 2 years follow up, 32 (49,2%) male, pts mean age was 28,5 (5,8) y., average disease duration 24,1 (15,4) mo, 60 (92,3%) pts were HLA-B27 positive. At baseline all pts were NSAID-naïve, DMARD-naïve, anti-TNF-naïve. For 2 years all pts taking NSAIDs at therapeutic doses, part of the pts received sulfasalazine and anti-TNF. BMD was measured using dual energy x-ray absorptiometry (DXA) of the femoral neck (FN) and lumbar spine (LS) (L2–4) at baseline and after 1 year, and 2 years follow up. BMD reduction was defined as Z score ≤ -2 (at least one site).
Results Low BMD at baseline founded in 9 (13,8%) pts, in 10 (15,3%) pts after 1 year and in 5 (7,7%) pts after 2 years follow up. There were no significantly differences between the mean values of BMD at baseline and after 2 year, data are shown in the Table.
Conclusions Low BMD was quite rare (14%) in patients with early axSpA. Small frequency of BMD reduction in the Russian cohort of axSpA patients after 2 years of study is probably due to disease activity decrease on anti-inflammatory therapy.
Disclosure of Interest None declared
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.